impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Elevated IL-1β levels in anti-Ro/SSA connective tissue diseases patients with prolonged corrected QTc interval

1, 2, 3, 4, 5, 6

 

  1. Rheumatology and Immunology Section, Department of Internal Medicine, CEMIC, University of Buenos Aires, Argentina.
  2. Pharmacology Unit, Dentistry School, University of Buenos Aires, and National Research Council of Argentina (CONICET), Buenos Aires, Argentina.
  3. Cardiology Section, Department of Internal Medicine, CEMIC, University of Buenos Aires, Argentina.
  4. Rheumatology and Immunology Section, Department of Internal Medicine, CEMIC, University of Buenos Aires, Argentina.
  5. Rheumatology and Immunology Section, Department of Internal Medicine, CEMIC, University of Buenos Aires, Argentina.
  6. Pharmacology Unit, Dentistry School, University of Buenos Aires, and National Research Council of Argentina (CONICET), Buenos Aires, Argentina.

CER8000
2015 Vol.33, N°5
PI 0715, PF 0720
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 26314292 [PubMed]

Received: 04/10/2014
Accepted : 30/04/2015
In Press: 27/08/2015
Published: 05/10/2015

Abstract

OBJECTIVES:
Patients with systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) have increased IL-1β levels. IL-1β and other pro-inflammatory cytokines have a modulating activity on cardiac ion channels and have been associated with increased arrhythmic risk in rheumatoid arthritis patients. Likewise, adult patients with connective tissue diseases (CTDs) may have prolonged QTc intervals associated with the presence of anti-Ro/SSA antibodies. Our objective was to evaluate the presence of serum IL-1β in subjects with CTDs, in relation to the presence of anti-Ro/SSA antibodies and QTc interval duration.
METHODS:
12-lead electrocardiograms (ECG) were performed and blood was withdrawn, measuring electrolytes, IL-1β anti-Ro/SSA antibodies by ELISA in 73 patients with CTDs.
RESULTS:
55 patients were anti-Ro/SSA positive and 18 were anti-Ro/SSA negative. Patients with anti-Ro/SSA positive antibodies had a significantly greater median IL-1β serum level: 7.29 (range: 0.17–17.3 pg/ml) compared to patients with anti-Ro/SSA negative antibodies whose median was: 1.67 (range 0.55–4.12 pg/ml) p<0.001. The mean QTc interval values obtained in both groups were not significantly different (417.7±23.1 vs. 414.7±21.2, p=0.63). The QTc interval was prolonged in 11 (20%) patients, who were all anti-Ro/SSA positive versus 0 (0 %) in anti-Ro/SSA negative patients p=0.05. Median IL-1β levels were: 8.7 (range: 2.69–15.1 pg/ml) in patients with prolonged QTc interval versus median: 5.0 (range: 0.17–17.3 pg/ml) in those with normal QTc interval values (<440ms) p=0.006.
CONCLUSIONS:
IL-1β is elevated in patients with CTDs that have both anti-Ro/SSA antibodies and prolonged QTc intervals.

Rheumatology Article